Global Stem Cell Manufacturing Market

Stem Cell Manufacturing Market Size, Share, Growth Analysis, By Product(Consumables (Culture Media, Other Consumables), Instruments (Bioreactors & Incubators, Cell Sorters), By Application (Research Applications (Life Science Research, Drug Discovery & Development), Clinical Applications (Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy)), By End User(Pharmaceutical & Biotechnology Companies, Academic Institutes, Research Laboratories, and Contract Research Organizations), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35B2172 | Region: Global | Published Date: October, 2024
Pages: 157 | Tables: 61 | Figures: 75

Stem Cell Manufacturing Market Dynamics

Stem Cell Manufacturing Market Drivers

Advances in Regenerative Medicine 

  • The rising interest in regenerative medicine significantly drives demand for stem cell production. New technologies and methods allow the possible applications of stem cells to increase, for instance, from generating bespoke treatments to managing chronic diseases. This advances the demand for stem cell goods and services in both clinical and research settings and further promotes more funding for the research and development of stem cells. 

Increasing Incidence of Chronic Diseases 

  • The increasing cases of chronic conditions such as diabetes, heart problems, and neurological diseases call for the need to use stem cell therapy treatment. Healthcare organizations are constantly looking for means of handling these challenging diseases, thus increasing the demand for therapies based on the use of stem cells. This factor is therefore forcing more investments in the application of clinical use for the technology based on stem cells. 

Restraints  

Regulatory Obstacles Regarding Stem Cell Applications 

  • There are a lot of barriers that the stem cell manufacturing industry has to face before getting into the challenging and complicated regulatory field. With stiff regulations regarding the application of stem cells in lab experiments and clinical trials, it will tend to elongate product development and approval cycles. Firms cannot avoid these shackles but seek ingenuity within them; hence they will lessen investment and limit expansion of the market. 

Ethical Issues of Embryonic Stem Cells 

  • Ethical issues surrounding the application of embryonic stem cells continue to heavily limit the market. Funding for research related to the same may be withheld and regulatory limits may be imposed owing to public anxieties regarding the ethical implications of stem cell research. Such ethical dilemmas would further limit the application of some stem cell treatments within the medical fraternity and in society and also impede their discovery.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Stem Cell Manufacturing Market size was valued at USD 12.58 Billion in 2022 and is poised to grow from USD 13.76 Billion in 2023 to USD 28.23 Billion by 2031, at a CAGR of 9.4% during the forecast period (2024-2031).

The highly competitive global stem cell manufacturing industry includes many companies that compete for market share and a competitive advantage. This market comprises research institutes, biotechnology companies, and international pharmaceutical firms. To strengthen their capability to manufacture stem cells and increase their products, these companies are constantly conducting research and development. The leading companies in the industry are working on innovative manufacturing technologies, improving cell culture techniques, and making stem cell production reproducible and scalable. It is believed that these efforts will be able to capitalize on market opportunities and meet the demand for cell-based therapies. 'Thermo Fisher Scientific, Inc. ', 'Merck KGaA ', 'Lonza Group Ltd. ', 'Danaher Corporation ', 'Sartorius AG ', 'Becton, Dickinson and Company ', 'Eppendorf SE ', 'Corning Incorporated ', 'Bio-Rad Laboratories, Inc. ', 'Takara Bio Inc. ', 'Fujifilm Holdings Corporation ', 'Getinge AB ', 'Terumo Corporation ', 'Bio-Techne Corporation ', 'Himedia Laboratories Pvt. Ltd. ', 'Stemcell Technologies, Inc. ', 'Miltenyi Biotec GmbH ', 'Promocell ', 'Anterogen Co. Ltd. ', 'Cellgenix GmbH ', 'Pluristem Therapeutics Inc. ', 'Daiichi Sankyo ', 'Organogenesis Holdings Inc. ', 'Vericel Corp. ', 'American Cryostem Corp.'

The rising interest in regenerative medicine significantly drives demand for stem cell production. New technologies and methods allow the possible applications of stem cells to increase, for instance, from generating bespoke treatments to managing chronic diseases. This advances the demand for stem cell goods and services in both clinical and research settings and further promotes more funding for the research and development of stem cells. 

Combining Cutting-Edge Technologies: One of the key stem cell manufacturing trends includes combination of advanced technologies. With 3D bioprinting and CRISPR gene editing on the rise as the most recent technological advances, this field is moving in strides. Thus, more streamlined and accurate manufacturing of stem cells along with more significant research are to be conducted within this domain, leading to much more productive therapy and subsequent interest and funding. 

As per the stem cell manufacturing market forecast, North America dominated the industry. Among such drivers of growth are the intensive stem cell research, significant public-private funding and grant for the clinical evaluation of stem cells for various purposes, a robust research infrastructure, and growing public appreciation of the therapeutic potential of stem cells. For instance, in April 2022, the Stem Cell Network (SCN) of Canada revealed IGNITE 2022-2025, which is the three-year strategic plan funded by the Government of Canada under its commitment from Budget 2021 for USD 45 million. Training, knowledge mobilization, and research can be announced to be the three main pillars of IGNITE 2022-2025. As SCN is set out to put scientists and the knowledge that emanates from Canada at the helm of world regenerative medicine (RM), each is very core to it.  

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Stem Cell Manufacturing Market

Report ID: SQMIG35B2172

$5,300
BUY NOW GET FREE SAMPLE